Phase 1
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:

Drug Details

ORIN1001 is an investigational first-in-class small molecule drug that has a novel molecular target, novel mechanism of action and a novel chemical structural class and identity. 

Study Purpose

This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib).

Find a Clinical Trial